SCHEMBL476677

SCHEMBL476677

Cc1cc2cccc(F)c2n1CCCNS(=O)(=O)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.40
CNR2 P34972 5/20 0.40
CNR1 P21554 1/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
USP2 O75604 1/20 0.37
ESR1 P03372 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CASP1 P29466 1/20 0.37
CYP2C19 P33261 1/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
TRPV4 Q9HBA0 3/20 0.37
EPHX1 P07099 1/20 0.37
FGB P02675 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL476711 0.87 PTGS1 (0.39) SMN1; SMN2CNR2CNR1MEN1KMT2A
SCHEMBL476538 0.87 SMN1; SMN2 (0.40) SMN1; SMN2CNR2MEN1KMT2AUSP2
SCHEMBL3299836 0.74 SMN1; SMN2 (0.37) SMN1; SMN2CNR2CNR1MEN1KMT2A
SCHEMBL3296244 0.74 SMN1; SMN2 (0.37) SMN1; SMN2CNR2CNR1MEN1KMT2A
SCHEMBL7783060 0.74 TLR8 (0.46) SMN1; SMN2CNR2CNR1MEN1KMT2A
SCHEMBL20504690 0.72 SMN1; SMN2 (0.39) SMN1; SMN2MEN1KMT2AUSP2ESR1
SCHEMBL476681 0.72 MEN1 (0.39) SMN1; SMN2CNR2MEN1KMT2AUSP2
SCHEMBL476604 0.72 RECQL (0.41) CNR2MEN1KMT2AUSP2ESR1
SCHEMBL476636 0.71 HTR7 (0.39) MEN1KMT2AUSP2ESR1CYP1A2
SCHEMBL7868647 0.68 EPHX1 (0.33) CYP1A2CYP2C19TRPV4EPHX1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951225-B1 3-ACYLINDOLE DERIVATIVES THE PREPARATION AND THE THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
US-7741363-B2 3-Acylindole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-06-22 US disclosed
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275102-A1 3-ACYLINDOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF F12, ECI1, NQO2 SMN1; SMN2 2155/4885CNR2 31/4885CNR1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.